• Most Popular
  • Most Shared

GTC Biotherapeutics drug gets fast-track status

Tue Sep 4, 2007 9:08am EDT

Stocks

   

NEW YORK, Sept 4 (Reuters) - GTC Biotherapeutics Inc (GTCB.O) said on Tuesday its ATryn drug has been designated as a fast track product by the Food and Drug Administration for the hereditary antithrombin deficiency indication.

Regulatory News

ATryn is being investigated in a late-stage study for the treatment of hereditary antithrombin deficiency for patients at risk of developing deep vein thrombosis or thromboembolism while undergoing surgical procedures or childbirth.

Top-line data from this study is planned to be available late in the fourth quarter. (Reporting by Christopher Kaufman)

Regulatory News


More from Reuters

Photo

Obama blames "systemic failures" in U.S. security

KANEOHE, Hawaii (Reuters) - President Barack Obama on Tuesday blamed a combination of "human and systemic failures" for allowing the botched Christmas Day attack aboard a Detroit-bound U.S. airliner, in his first big test on homeland security. | Video

» More Top News
Leaves gather in front of an empty and boarded-up house in Youngstown, Ohio November 21, 2009. REUTERS/Brian Snyder

Castles built on sand

Rust-belt American cities like Youngstown, Ohio were battered by the downturn. Now they're ready to move on, but it won’t be easy. The first in a three-part report.  Full Article 

Route to Recovery
REUTERS/James Saft
JAMES SAFT:

Welcome to the "Teenies"

Shrinking financial sector? Paltry investment returns? Welcome to the the next decade. Don't worry, there's some good news, too.  Commentary 

COMMENTARY